Answer
Nov 07, 2024 - 01:52 PM
Xeljanz (tofacitinib) is considered a high-risk medication due to its potential for serious side effects, including an increased risk of blood clots, serious infections, and certain cancers. The FDA has issued warnings about these risks, especially when used at higher doses or in patients with pre-existing risk factors. It is important for patients to discuss their individual risk factors with their healthcare provider before starting treatment with Xeljanz.
